tradingkey.logo
tradingkey.logo
Search

Transcode Therapeutics Inc

RNAZ
Add to Watchlist
4.750USD
-0.500-9.52%
Close 07-31 16:00ETQuotes delayed by 15 min
3.96MMarket Cap
LossP/E TTM

RNAZ Income Statement

You can find the annual or quarterly income statement of Transcode Therapeutics Inc here for insights into the performance and operational efficiency of Transcode Therapeutics Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
FY2021Q2
FY2021Q1
Operating expenses
154.63%7.19M
40.76%6.49M
110.78%4.54M
-20.46%4.07M
-13.45%2.82M
14.28%4.61M
-59.24%2.15M
17.78%5.11M
-32.35%3.26M
-21.13%4.03M
22.90%5.28M
-7.08%4.34M
38.93%4.82M
82.78%5.11M
84.63%4.30M
1465.47%4.67M
672.14%3.47M
--2.80M
--2.33M
--298.48K
--449.46K
R&D expenses
130.09%5.11M
50.49%5.48M
157.54%3.16M
-16.73%2.57M
26.18%2.22M
8.17%3.64M
-63.28%1.23M
3.90%3.08M
-32.12%1.76M
25.19%3.36M
9.81%3.34M
13.20%2.97M
37.72%2.59M
109.00%2.69M
206.56%3.04M
1137.31%2.62M
613.37%1.88M
--1.29M
--992.95K
--211.75K
--263.76K
Depreciation, depletion, and amortization
-53.23%23.94K
-63.55%44.78K
-96.25%4.78K
-90.59%13.44K
-63.87%51.17K
-12.35%122.86K
-8.11%127.52K
3.81%142.83K
41.37%141.65K
375.08%140.17K
459.56%138.78K
506.18%137.59K
363.86%100.20K
1.78%29.50K
229.16%24.80K
--22.70K
--21.60K
--28.99K
--7.54K
----
----
Other operating expenses
59.80%-139.84K
-55.48%-754.16K
-85.51%-22.17K
---153.69K
-1185.60%-347.84K
-1680.08%-485.05K
56.44%-11.95K
100.00%0.00
65.93%-27.06K
92.90%-27.25K
95.81%-27.44K
-2171.63%-788.94K
-1036.04%-79.41K
-102.47%-383.77K
-1963.81%-654.95K
39.12%-34.73K
---6.99K
---189.55K
---31.73K
---57.05K
--0.00
Operating profit
-154.63%-7.19M
-40.76%-6.49M
-110.78%-4.54M
20.46%-4.07M
13.45%-2.82M
-14.28%-4.61M
59.24%-2.15M
-17.78%-5.11M
32.35%-3.26M
21.13%-4.03M
-22.90%-5.28M
7.08%-4.34M
-38.93%-4.82M
-82.78%-5.11M
-84.63%-4.30M
-1465.47%-4.67M
-672.14%-3.47M
---2.80M
---2.33M
---298.48K
---449.46K
Net non-operating interest income (expenses)
Non-operating interest income
62836.99%91.89K
49432.70%78.76K
-17.88%147.00
-16.85%148.00
-13.10%146.00
16.06%159.00
36.64%179.00
-27.64%178.00
-96.48%168.00
-98.58%137.00
-98.54%131.00
-81.52%246.00
979.19%4.77K
1789.41%9.64K
6283.69%9.00K
133000.00%1.33K
3583.33%442.00
--510.00
--141.00
--1.00
--12.00
Non-operating interest expense
-100.00%0.00
-70.41%542.00
-44.77%5.96K
----
-98.83%114.00
-96.72%1.83K
-37.55%10.79K
--4.48K
--9.71K
74.76%55.90K
--17.28K
----
----
--31.99K
-100.00%0.00
-100.00%0.00
-100.00%0.00
--0.00
--333.00
--41.97K
--52.77K
Gains from sale of securities
22.36%-21.11K
-102.34%-5.34K
79.63%-32.05K
34.59%-47.49K
50.88%-27.19K
--228.20K
---157.31K
---72.59K
---55.35K
----
----
----
----
----
----
----
----
----
----
----
----
Special income (expenses)
-13.00%-10.44M
-624.91%-6.80M
---279.16K
---161.71K
---9.23M
---938.69K
----
----
----
----
----
----
----
----
100.00%0.00
-100.00%0.00
100.00%0.00
--0.00
---1.34K
--3.11M
---3.98M
- Gains from disposal of fixed assets
----
----
----
----
----
--500.00
----
----
----
----
----
----
----
----
----
----
----
---3.08K
----
----
----
Other non-operating income (expenses)
----
630.69%3.17M
----
----
----
---596.96K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Income before tax
-45.25%-17.55M
-123.41%-13.22M
-109.19%-4.86M
17.61%-4.28M
-263.27%-12.09M
-44.73%-5.92M
56.20%-2.32M
-19.56%-5.19M
30.94%-3.33M
20.38%-4.09M
-23.55%-5.30M
7.06%-4.34M
-38.81%-4.82M
-83.41%-5.13M
-84.13%-4.29M
-268.58%-4.67M
22.64%-3.47M
---2.80M
---2.33M
--2.77M
---4.49M
Income tax
--231.31K
--226.07K
----
----
--0.00
----
----
----
----
----
----
----
----
----
----
----
----
----
----
--0.00
--0.00
Income after tax
-47.16%-17.79M
-127.23%-13.44M
-109.19%-4.86M
17.61%-4.28M
-263.27%-12.09M
-44.73%-5.92M
56.20%-2.32M
-19.56%-5.19M
30.94%-3.33M
20.38%-4.09M
-23.55%-5.30M
7.06%-4.34M
-38.81%-4.82M
-83.41%-5.13M
-84.13%-4.29M
-268.58%-4.67M
22.64%-3.47M
---2.80M
---2.33M
--2.77M
---4.49M
Net income from continuous operations
-47.16%-17.79M
-127.23%-13.44M
-109.19%-4.86M
17.61%-4.28M
-263.27%-12.09M
-44.73%-5.92M
56.20%-2.32M
-19.56%-5.19M
30.94%-3.33M
20.38%-4.09M
-23.55%-5.30M
7.06%-4.34M
-38.81%-4.82M
-83.41%-5.13M
-84.13%-4.29M
-268.58%-4.67M
22.64%-3.47M
---2.80M
---2.33M
--2.77M
---4.49M
Other net gains and losses
----
--1.00
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Net Income attributable to non-controlling interests
----
--1.61M
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Net income attributable to controlling interests
-61.44%-19.51M
-153.14%-15.05M
-109.19%-4.86M
17.61%-4.28M
-263.27%-12.09M
-45.48%-5.95M
56.20%-2.32M
-19.56%-5.19M
30.94%-3.33M
20.38%-4.09M
-23.55%-5.30M
7.06%-4.34M
-38.81%-4.82M
-83.41%-5.13M
-84.13%-4.29M
-268.58%-4.67M
22.64%-3.47M
---2.80M
---2.33M
--2.77M
---4.49M
Preferred share dividend
--1.73M
5161.96%1.61M
----
----
----
--30.60K
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
Net income attributable to common shareholders
-61.44%-19.51M
-153.14%-15.05M
-109.19%-4.86M
17.61%-4.28M
-263.27%-12.09M
-45.48%-5.95M
56.20%-2.32M
-19.56%-5.19M
30.94%-3.33M
20.38%-4.09M
-23.55%-5.30M
7.06%-4.34M
-38.81%-4.82M
-83.41%-5.13M
-84.13%-4.29M
-268.58%-4.67M
22.64%-3.47M
---2.80M
---2.33M
--2.77M
---4.49M
Basic earnings per share
69.67%-21.28
93.96%-16.49
96.01%-5.82
99.25%-5.13
88.26%-70.16
95.75%-272.98
99.67%-146.07
99.44%-680.22
99.76%-597.77
97.80%-6.42K
81.68%-44.76K
54.30%-121.61K
-25.09%-247.26K
-82.36%-292.41K
-63.54%-244.34K
-160.23%-266.08K
72.36%-197.66K
---160.35K
---149.41K
--441.79K
---715.15K
Diluted earnings per share
69.67%-21.28
93.96%-16.49
96.01%-5.82
99.25%-5.13
88.26%-70.16
95.75%-272.98
99.67%-146.07
99.44%-680.22
99.76%-597.77
97.80%-6.42K
81.68%-44.76K
54.30%-121.61K
-25.09%-247.26K
-82.36%-292.41K
-63.54%-244.34K
-170.15%-266.08K
72.36%-197.66K
---160.35K
---149.41K
--379.29K
---715.15K
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Transcode Therapeutics Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing RNAZ stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Transcode Therapeutics Inc's net income for the year?

Transcode Therapeutics Inc posted -36.27M in net income for fiscal year 2025.

How much net income did Transcode Therapeutics Inc post in the last quarter?

Transcode Therapeutics Inc reported -19.51M in net income for the latest quarter。

What was Transcode Therapeutics Inc's annual operating profit?

Transcode Therapeutics Inc's operating income was -17.92M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.